What is Stelara and how does it treat Crohn’s disease?
Stelara (ustekinumab) is a human monoclonal antibody that blocks the p40 subunit shared by interleukins‑12 and ‑23. By dampening these inflammatory pathways, it reduces intestinal inflammation in patients with moderate‑to‑severe Crohn’s disease who have not responded to conventional therapy or another biologic [1].
How do the clinical trials back its use?
The UNITI‑1, UNITI‑2, and SEAVUE studies enrolled adults with active Crohn’s disease. After a single 6‑mg/kg IV loading dose, patients receiving 90‑mg subcutaneous injections every eight weeks achieved clinical remission in roughly 25‑30 % of cases, while those on 90‑mg every four weeks reached remission in 35‑40 % of cases. These results earned FDA approval in 2016 and have been replicated in real‑world registries that confirm its efficacy and durability over several years [2].
What are the usual dosing guidelines?
- Induction: 6‑mg/kg IV infusion over 2–3 h.
- Maintenance: 90‑mg SC every eight weeks, or 90‑mg SC every four weeks for patients with a history of high disease activity.
Switching from an anti‑TNF drug to Stelara usually follows a 6‑month wash‑out to avoid overlapping immunosuppression [3].
What side effects should patients watch for?
Common adverse events include upper respiratory infections, headache, nausea, and mild elevations in liver enzymes. Serious infections (e.g., tuberculosis, opportunistic fungal infections) are rare but monitored. The risk of malignancy has not increased beyond that seen with other biologics in long‑term studies [4].
How does Stelara stack up against other biologics?
Compared with anti‑TNF agents (adalimumab, infliximab, golimumab), Stelara has a comparable remission rate but a lower incidence of injection site reactions and anti‑drug antibodies. It also offers a convenient every‑four‑to‑eight‑week schedule, which may improve adherence. Vedolizumab, which blocks gut‑specific integrin α4β7, has a slightly slower onset of action but similar long‑term outcomes. Direct head‑to‑head trials are scarce, so decisions often hinge on prior biologic exposure and patient preference [5].
Will biosimilars or other competitors appear soon?
No ustekinumab biosimilar has reached the U.S. market yet, largely because the patent on the recombinant protein is still active. However, several companies are filing for generic versions of the drug’s active ingredient, and a biosimilar for the 90‑mg SC formulation is expected by 2029 under the new biologic‑drug regulation pathway [6].
What does the patent landscape look like?
The primary patent covering Stelara’s molecular structure is set to expire in 2027, with secondary patents extending exclusivity until 2030. A drug‑patent‑watch site tracks these dates and indicates that the next window for generic entry will likely close after 2030 unless litigation or regulatory changes intervene [7].
How does insurance and cost factor into the decision?
The average wholesale price for a 90‑mg vial is around $3,000. Most Medicare Advantage, commercial, and Medicaid plans cover Stelara under a step‑therapy protocol that requires failure of an anti‑TNF agent before approval. Patient assistance programs and manufacturer copay cards can reduce out‑of‑pocket costs for qualifying patients [8].
Is there a patient assistance program?
Yes. Johnson & Johnson offers a program that covers copays, co‑insurance, and prior authorization support for patients who meet eligibility criteria. Details are available on the company’s website and through the insurer’s pharmacy benefit manager.
---
Sources
- https://www.drugpatentwatch.com/ustekinumab
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378233/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742793/
- https://www.fda.gov/media/122944/download
- https://www.medscape.com/viewarticle/814795
- https://www.bioworld.com/articles/427656
- https://www.drugpatentwatch.com/ustekinumab-patents
- https://www.jnj.com/patients-helps